Nanogen Launches Cystic Fibrosis Analyte Specific Reagents

Mar 23, 2006, 00:00 ET from Nanogen, Inc.

    SAN DIEGO, March 23 /PRNewswire-FirstCall/ -- Nanogen, Inc.
 (Nasdaq:   NGEN), developer of advanced diagnostic products, announced today it
 has expanded its molecular reagent product portfolio with analyte specific
 reagents (ASRs) designed to detect 23 wild type and mutation sequences
 associated with cystic fibrosis (CF).  The U.S. launch of the product is
 occurring at the American College of Medical Genetics (ACMG) meeting taking
 place March 23-26 in San Diego, California, where medical geneticists and
 other health care professionals can discuss the new products with Nanogen
     The new CFTR ASR products are part of the company's growing NGEN(TM) brand
 of reagents for molecular applications.  The NGEN(TM) CFTR ASR can be used by
 CLIA laboratories to develop and validate assays to genotype the 23 mutations
 and polymorphisms recommended by the American College of Obstetricians and
 Gynecologists (ACOG) and the ACMG for CF carrier screening.  Assays using
 NGEN(TM) CFTR ASRs, once validated by the laboratory, can be used as a
 clinical diagnostic test.  ACOG has recommended, as a standard of care, that
 all Caucasians or Ashkenazi Jews be offered CF carrier screening prior to
 conceiving a child.  The products will be CE marked in Europe for in vitro
 diagnostics and will be available in the United States as ASRs for which
 analytical and performance characteristics are not established.
     "Laboratories face a confusing menu of choices when they look to invest in
 CF screening reagents.  By choosing the NGEN(TM) CFTR ASRs, labs can implement
 a simple solution for carrier screening that meets the standard of care,"
 noted Graham Lidgard, senior vice president of research and development at
 Nanogen.  "By combining the recommended test with genetic counseling,
 laboratories and physicians will be able to deliver sound information to their
     CF is one of the most common genetic disorders in Caucasian populations of
 European descent, carried by about 1 in 29 Caucasians.  CF is characterized by
 pulmonary and gastrointestinal symptoms of varying severity, but most CF cases
 are associated with substantial illness and shortened lifespan and require
 lifelong medical care.  CF is an autosomal recessive genetic disorder.  To
 express the disease, a child must inherit two copies of the defective gene,
 one from each parent.  Many people carry a single CF mutation and do not
 experience any significant health problems as a result.  Couples who are both
 carriers have a one in four chance of having a child with CF.
     About Nanogen, Inc.
     Nanogen's advanced technologies provide researchers, clinicians and
 physicians worldwide with improved methods and tools to predict, diagnose, and
 ultimately help treat disease.  The company's products include real-time PCR
 reagents, the NanoChip(R) electronic microarray platform and a line of
 reagents useful in rapid diagnostic tests.  Nanogen's ten years of pioneering
 research involving nanotechnology holds the promise of miniaturization and
 continues to be supported for its potential for diagnostic and biowarfare
 applications.  For additional information please visit Nanogen's website at
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether
 products under development can be successfully developed and commercialized,
 whether patents owned or licensed by Nanogen will be developed into products,
 whether the patents owned by Nanogen offer any protection against competitors
 with competing technologies, whether results reported by our customers or
 partners can be identically replicated, and other risks and uncertainties
 discussed under the caption "Factors That May Affect Results" and elsewhere in
 Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
 Exchange Commission.  These forward-looking statements speak only as of the
 date hereof. Nanogen disclaims any intent or obligation to update these
 forward-looking statements.

SOURCE Nanogen, Inc.